Trial Profile
Clinical experience with tyrosine kinase inhibitors, erlotinib and gefitinib in lung cancer patients in a New Zealand tertiary referral centre over a period of funding change
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2017
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Apr 2017 New trial record
- 03 Mar 2017 Results published in the New Zealand Medical Journal